Marina V Backer

Summary

Affiliation: Case Western Reserve University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature
    Marina V Backer
    SibTech, Inc, Newington, CT 06111, USA
    Mol Cancer Ther 4:1423-9. 2005
  2. ncbi request reprint Overexpression of NM23-1 enhances responsiveness of IMR-32 human neuroblastoma cells to differentiation stimuli
    M V Backer
    SibTech, Inc, Newington, CT 06111, USA
    Anticancer Res 20:1743-9. 2000
  3. pmc Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells
    Joseph M Backer
    SibTech, Inc, Brookfield, CT 06804, USA
    Neoplasia 11:1165-73. 2009
  4. ncbi request reprint Self-assembled "dock and lock" system for linking payloads to targeting proteins
    Marina V Backer
    SibTech, Inc, Newington, Connecticut 06111, USA
    Bioconjug Chem 17:912-9. 2006
  5. ncbi request reprint Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag
    Marina V Backer
    SibTech, Inc, Newington, CT 06111, USA
    Biomaterials 27:5452-8. 2006
  6. ncbi request reprint Adapter protein for site-specific conjugation of payloads for targeted drug delivery
    Marina V Backer
    Rammelkamp Center for Research, Case Western Reserve University School of Medicine, Cleveland, Ohio 44109, USA
    Bioconjug Chem 15:1021-9. 2004
  7. ncbi request reprint Assembly of targeting complexes driven by a single-chain antibody
    Marina V Backer
    SibTech, Inc, Newington, CT 06111, USA
    J Immunol Methods 289:37-45. 2004
  8. ncbi request reprint Humanized docking system for assembly of targeting drug delivery complexes
    Marina V Backer
    SibTech, Inc, 705 North Mountain Road, Newington, CT 06111, USA
    J Control Release 89:499-511. 2003
  9. ncbi request reprint Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery
    Marina V Backer
    SibTech Inc, 705 North Mountain Road, Newington, CT 06111, USA
    Protein Expr Purif 26:455-61. 2002
  10. ncbi request reprint Molecular vehicles for targeted drug delivery
    Marina V Backer
    SibTech, Inc, Newington, Connecticut 06111, USA
    Bioconjug Chem 13:462-7. 2002

Research Grants

  1. Targeted Delivery of Anthrax Inhibitors
    Marina Backer; Fiscal Year: 2007

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature
    Marina V Backer
    SibTech, Inc, Newington, CT 06111, USA
    Mol Cancer Ther 4:1423-9. 2005
    ..Our data lay the groundwork for future studies using the VEGF-BD/Cy5 bioconjugate as a targeting agent for BNCT of tumor neovasculature...
  2. ncbi request reprint Overexpression of NM23-1 enhances responsiveness of IMR-32 human neuroblastoma cells to differentiation stimuli
    M V Backer
    SibTech, Inc, Newington, CT 06111, USA
    Anticancer Res 20:1743-9. 2000
    ..These genes encode nucleoside diphosphate kinases A and B that form free or bound homo- and heteromers, which are distributed between soluble and particulate fractions of cells and display catalytic and non-catalytic activities...
  3. pmc Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells
    Joseph M Backer
    SibTech, Inc, Brookfield, CT 06804, USA
    Neoplasia 11:1165-73. 2009
    ....
  4. ncbi request reprint Self-assembled "dock and lock" system for linking payloads to targeting proteins
    Marina V Backer
    SibTech, Inc, Newington, Connecticut 06111, USA
    Bioconjug Chem 17:912-9. 2006
    ..We expect that this self-assembled "dock and lock" system will provide new opportunities for using functionally active proteins for biomedical purposes...
  5. ncbi request reprint Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag
    Marina V Backer
    SibTech, Inc, Newington, CT 06111, USA
    Biomaterials 27:5452-8. 2006
    ....
  6. ncbi request reprint Adapter protein for site-specific conjugation of payloads for targeted drug delivery
    Marina V Backer
    Rammelkamp Center for Research, Case Western Reserve University School of Medicine, Cleveland, Ohio 44109, USA
    Bioconjug Chem 15:1021-9. 2004
    ..Targeting proteins, Hu-tagged vascular endothelial growth factor or Hu-tagged annexin V, were docked to liposomes decorated with HuS, and the assembled complexes delivered liposomes selectively to target cells...
  7. ncbi request reprint Assembly of targeting complexes driven by a single-chain antibody
    Marina V Backer
    SibTech, Inc, Newington, CT 06111, USA
    J Immunol Methods 289:37-45. 2004
    ....
  8. ncbi request reprint Humanized docking system for assembly of targeting drug delivery complexes
    Marina V Backer
    SibTech, Inc, 705 North Mountain Road, Newington, CT 06111, USA
    J Control Release 89:499-511. 2003
    ..Targeting DNA delivery complexes were assembled, characterized by dynamic light scattering, and found to be very effective in receptor-mediated DNA delivery...
  9. ncbi request reprint Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery
    Marina V Backer
    SibTech Inc, 705 North Mountain Road, Newington, CT 06111, USA
    Protein Expr Purif 26:455-61. 2002
    ..After the removal of S-peptide, both fragments retain the ability to bind S-peptide and S-peptide-tagged proteins. The 122cys residue in the mutant fragment is available for site-specific conjugation...
  10. ncbi request reprint Molecular vehicles for targeted drug delivery
    Marina V Backer
    SibTech, Inc, Newington, Connecticut 06111, USA
    Bioconjug Chem 13:462-7. 2002
    ..We expect that our strategy can be employed for targeted delivery of many therapeutic or imaging agents by different recombinant targeting proteins...
  11. ncbi request reprint Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2
    M V Backer
    SibTech Inc, 705 North Mountain Road, Newington, CT 06111, USA
    J Control Release 74:349-55. 2001
    ..The selective cytotoxicity of SLT-VEGF proteins against growing endothelial cells overexpressing VEGFR-2 suggests that they may be useful in targeting similar cells at sites of angiogenesis...
  12. ncbi request reprint Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins
    M V Backer
    SibTech, Inc, Newington, Connecticut 06111, USA
    Bioconjug Chem 12:1066-73. 2001
    ..Selective cytotoxicity of SLT-VEGF/L against growing endothelial cells overexpressing VEGFR-2 suggests that it may be useful in targeting similar cells at the sites of angiogenesis...
  13. ncbi request reprint Functionally active VEGF fusion proteins
    M V Backer
    Sib Tech, Incorporated, 705 North Mountain Road, Newington, Connecticut 06111, USA
    Protein Expr Purif 23:1-7. 2001
    ..We hypothesize that VEGF fusion proteins may be employed for targeting endothelial cells at the sites of angiogenesis...
  14. ncbi request reprint Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery
    Timur I Gaynutdinov
    SibTech, Inc, Newington, CT 06111, USA
    Protein Eng 16:771-5. 2003
    ..The affinity of HuS obtained from BH-RNase to Hu-tag is approximately five times higher than that for recombinant HuS, reflecting a higher percentage of properly folded proteins...
  15. doi request reprint A "dock and lock" approach to preparation of targeted liposomes
    Marina V Backer
    SibTech, Inc, Brookfield, CT, USA
    Methods Mol Biol 605:257-66. 2010
    ..We expect that our "dock and lock" strategy will open new opportunities for development of targeted therapeutic liposomes for research and clinical use...
  16. pmc Inhibition of anthrax protective antigen outside and inside the cell
    Marina V Backer
    SibTech, Inc, 705 North Mountain Road, Newington, CT 06111, USA
    Antimicrob Agents Chemother 51:245-51. 2007
    ..These data suggest the potential for the use of beta-cyclodextrins in combination with LFn-Lip loaded with antianthrax drugs against intracellular targets...
  17. doi request reprint Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins
    Marina V Backer
    SibTech Inc, Brookfield, CT, USA
    Methods Mol Biol 494:275-94. 2008
    ..We expect that Cys-tag would provide new opportunities for development of targeted therapeutic and imaging agents for research and clinical use...
  18. ncbi request reprint Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
    Marina V Backer
    SibTech, Inc, 705 North Mountain Road, Newington, Connecticut 06111, USA
    Nat Med 13:504-9. 2007
    ..We expect that multimodal imaging of VEGF receptors with these probes will be useful for clinical diagnosis and therapeutic monitoring, and will help to accelerate the development of new angiogenesis-directed drugs and treatments...
  19. doi request reprint Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature
    Marina V Backer
    SibTech, Inc, Brookfield, Connecticut 06804, USA
    Adv Genet 67:1-27. 2009
    ..We describe here one such molecule, SLT-VEGF, a fusion protein containing VEGF121 and the highly cytotoxic catalytic subunit of Shiga-like toxin...
  20. doi request reprint Targeting the unfolded protein response in cancer therapy
    Marina V Backer
    SibTech, Inc, Brookfield, Connecticut, USA
    Methods Enzymol 491:37-56. 2011
    ..In this chapter, we provide experimental protocols for the assessment of the effects of EGF-SubA on EGFR-positive cancer cells, either alone or in combination with UPR-inducing drugs...
  21. pmc Imaging key biomarkers of tumor angiogenesis
    Marina V Backer
    SibTech, Inc Brookfield, CT 06804, USA
    Theranostics 2:502-15. 2012
    ..Further work will define the competitiveness of targeted imaging of key angiogenesis markers for early diagnostic and image-guided therapy...
  22. ncbi request reprint Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT)
    B T S Thirumamagal
    Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, 43210, USA
    Bioconjug Chem 17:1141-50. 2006
    ....
  23. ncbi request reprint Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy
    Gong Wu
    Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, Ohio 43210, USA
    Anticancer Agents Med Chem 6:167-84. 2006
    ..Finally, we will conclude with a discussion relating to issues that must be addressed if these HMW agents are to be used clinically...
  24. ncbi request reprint Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor
    Francis G Blankenberg
    Department of Pediatrics, Stanford University, Stanford, California 94304, USA
    J Nucl Med 45:1373-80. 2004
    ..The assembly of this complex is based on interactions between human 109-amino acid (HuS) and 15-amino acid (Hu-tag) fragments of ribonuclease I, which serve as an "Adapter protein" and a Docking tag, respectively...
  25. ncbi request reprint In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF
    Francis G Blankenberg
    Division of Nuclear Medicine Department of Radiology and MIPS Molecular Imaging Program at Stanford, Stanford University, Stanford, CA 94304, USA
    Eur J Nucl Med Mol Imaging 33:841-8. 2006
    ..We wished to test (99m)Tc-HYNIC-C-tagged VEGF ((99m)Tc-HYNIC-VEGF) for the imaging of tumor vasculature before and after antiangiogenic (low continuous dosing, metronomic) and tumoricidal (high-dose) cyclophosphamide treatment...
  26. pmc VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation
    Marcia R Saban
    Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Am J Physiol Renal Physiol 295:F60-72. 2008
    ....

Research Grants2

  1. Targeted Delivery of Anthrax Inhibitors
    Marina Backer; Fiscal Year: 2007
    ..In Phase II we will develop LFn-liposomes with combination of LF and EF inhibitors, validate these liposomes in animal models of anthrax infection, and pre-clinical steps required for IND filing. ..